CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Jazz Pharmaceuticals plc - JAZZ CFD

107.05
1.28%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Jazz Pharmaceuticals PLC ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 108.44
Open* 108.28
1-Year Change* -25.43%
Day's Range* 106.46 - 108.77
52 wk Range 111.25-158.64
Average Volume (10 days) 574.24K
Average Volume (3 months) 14.64M
Market Cap 7.25B
P/E Ratio 190.95
Shares Outstanding 62.96M
Revenue 3.79B
EPS 0.60
Dividend (Yield %) N/A
Beta 0.62
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 16, 2024 108.44 -1.55 -1.41% 109.99 110.60 108.38
Apr 15, 2024 110.64 0.22 0.20% 110.42 112.17 109.95
Apr 12, 2024 110.51 -1.78 -1.59% 112.29 112.78 109.94
Apr 11, 2024 113.39 -0.32 -0.28% 113.71 114.56 112.25
Apr 10, 2024 113.93 1.01 0.89% 112.92 114.24 112.23
Apr 9, 2024 113.96 -0.95 -0.83% 114.91 115.80 112.43
Apr 8, 2024 114.99 -0.96 -0.83% 115.95 116.50 114.45
Apr 5, 2024 116.30 1.17 1.02% 115.13 116.76 114.34
Apr 4, 2024 115.01 -1.97 -1.68% 116.98 117.61 114.95
Apr 3, 2024 116.80 -0.24 -0.21% 117.04 117.60 115.95
Apr 2, 2024 117.51 -0.48 -0.41% 117.99 119.18 116.64
Apr 1, 2024 118.92 -0.91 -0.76% 119.83 119.94 117.97
Mar 28, 2024 120.18 0.69 0.58% 119.49 121.37 118.50
Mar 27, 2024 120.31 2.36 2.00% 117.95 120.42 117.50
Mar 26, 2024 117.83 -2.58 -2.14% 120.41 120.42 117.31
Mar 25, 2024 120.14 -1.66 -1.36% 121.80 123.52 120.14
Mar 22, 2024 120.99 -2.72 -2.20% 123.71 125.16 120.99
Mar 21, 2024 123.18 -1.11 -0.89% 124.29 125.69 122.84
Mar 20, 2024 124.65 1.26 1.02% 123.39 125.39 122.80
Mar 19, 2024 124.77 2.30 1.88% 122.47 124.95 122.47

Jazz Pharmaceuticals plc Events

Time (UTC) Country Event
Friday, August 2, 2024

Time (UTC)

13:45

Country

IE

Event

Jazz Pharmaceuticals PLC Annual Shareholders Meeting
Jazz Pharmaceuticals PLC Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 3659.37 3094.24 2363.57 2161.76 1890.92
Revenue 3659.37 3094.24 2363.57 2161.76 1890.92
Cost of Revenue, Total 540.517 440.76 148.917 127.93 121.544
Gross Profit 3118.86 2653.48 2214.65 2033.83 1769.38
Total Operating Expense 3724.9 2923.96 1990.59 1629.39 1277.51
Selling/General/Admin. Expenses, Total 1376.17 1222.68 854.233 736.942 683.53
Research & Development 1034.6 505.748 586.625 409.701 226.616
Depreciation / Amortization 599.169 525.769 259.58 354.814 201.498
Unusual Expense (Income) 174.448 229 141.239 0 44.321
Operating Income -65.528 170.278 372.973 532.374 613.413
Interest Income (Expense), Net Non-Operating -307.256 -283.116 -97.878 -78.072 -86.153
Net Income Before Taxes -372.784 -112.838 275.095 454.302 527.26
Net Income After Taxes -214.139 -328.954 241.578 527.456 447.091
Minority Interest
Net Income Before Extra. Items -224.06 -329.668 238.616 523.367 447.091
Net Income -224.06 -329.668 238.616 523.367 447.098
Income Available to Common Excl. Extra. Items -224.06 -329.668 238.616 523.367 447.091
Income Available to Common Incl. Extra. Items -224.06 -329.668 238.616 523.367 447.098
Dilution Adjustment 0
Diluted Net Income -224.06 -329.668 238.616 523.367 447.098
Diluted Weighted Average Shares 62.539 59.694 56.517 57.55 61.221
Diluted EPS Excluding Extraordinary Items -3.58272 -5.52263 4.22202 9.09413 7.30289
Diluted Normalized EPS -1.7696 -3.02908 6.4166 9.09413 7.91677
Total Extraordinary Items 0 0.0075
Equity In Affiliates -9.921 -0.714 -2.962 -4.089
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 957.317 892.812 972.123 940.652 932.878
Revenue 957.317 892.812 972.123 940.652 932.878
Cost of Revenue, Total 97.537 128.644 167.364 133.661 124.208
Gross Profit 859.78 764.168 804.759 806.991 808.67
Total Operating Expense 799.681 766.757 1235.51 915.889 847.332
Selling/General/Admin. Expenses, Total 340.844 297.917 383.203 317.678 325.673
Research & Development 209.238 190.41 547.555 148.87 208.195
Depreciation / Amortization 152.062 149.786 137.387 141.232 148.456
Unusual Expense (Income) 0 174.448 40.8
Operating Income 157.636 126.055 -263.386 24.763 85.546
Interest Income (Expense), Net Non-Operating -75.852 -70.954 -76.607 -84.893 -64.532
Net Income Before Taxes 81.784 55.101 -339.993 -60.13 21.014
Net Income After Taxes 106.107 70.425 -239.951 -17.103 37.126
Equity In Affiliates -1.669 -1.005 -0.773 -2.545 -2.461
Net Income Before Extra. Items 104.438 69.42 -240.724 -19.648 34.665
Net Income 104.438 69.42 -240.724 -19.648 34.665
Income Available to Common Excl. Extra. Items 104.438 69.42 -240.724 -19.648 34.665
Income Available to Common Incl. Extra. Items 104.438 69.42 -240.724 -19.648 34.665
Diluted Net Income 104.438 69.42 -240.724 -19.648 34.665
Diluted Weighted Average Shares 73.54 73.771 63.061 62.785 63.431
Diluted EPS Excluding Extraordinary Items 1.42015 0.94102 -3.81732 -0.31294 0.5465
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 1.42015 0.94102 -3.81732 1.49308 0.96459
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2606.14 2611.33 2839.57 1630.27 1234.01
Cash and Short Term Investments 881.482 591.448 2132.77 1077.34 824.622
Cash & Equivalents 517.464
Short Term Investments 30 80.701 1615.65 744.172 609.016
Total Receivables, Net 742.628 563.36 396.49 355.987 263.838
Accounts Receivable - Trade, Net 651.493 563.36 396.49 355.987 263.838
Total Inventory 714.061 1072.72 95.396 78.608 52.956
Prepaid Expenses 91.912 131.413 62.422 39.434 25.017
Other Current Assets, Total 176.057 252.392 152.491 78.895 67.572
Total Assets 10835.3 12298.6 6535.9 5538.9 5203.49
Property/Plant/Equipment, Total - Net 301.376 343.423 257.104 270.891 200.358
Property/Plant/Equipment, Total - Gross 409.023 428.794 324.692 326.148 249.966
Accumulated Depreciation, Total -107.647 -85.371 -67.588 -55.257 -49.608
Goodwill, Net 1692.66 1827.61 958.303 920.018 927.63
Intangibles, Net 5794.44 7152.33 2195.05 2440.98 2731.33
Other Long Term Assets, Total 440.64 363.945 285.875 276.743 110.164
Total Current Liabilities 933.193 809.303 653.745 364.49 345.487
Accounts Payable 90.758 100.298 26.945 47.545 40.602
Accrued Expenses 802.874 647.479 349.107 266.836 263.427
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 31.381 31.406 246.322 33.387 33.387
Other Current Liabilities, Total 8.18 30.12 31.371 16.722 8.071
Total Liabilities 7749.52 8333.45 2876.16 2427.92 2446.07
Total Long Term Debt 5698.55 6025.21 1848.52 1573.87 1563.03
Long Term Debt 5693.34 6018.94 1848.52 1573.87 1563.03
Deferred Income Tax 944.337 1300.54 130.397 224.095 309.097
Other Liabilities, Total 173.44 198.392 243.498 265.461 228.46
Total Equity 3085.73 3965.19 3659.75 3110.98 2757.42
Common Stock 0.061 0.061 0.061 0.061 0.061
Additional Paid-In Capital 3477.12 3534.79 2633.67 2266.03 2113.63
Retained Earnings (Accumulated Deficit) 734.058 830.698 1160.37 1068.29 841.522
Other Equity, Total -1125.51 -400.36 -134.352 -223.393 -197.791
Total Liabilities & Shareholders’ Equity 10835.3 12298.6 6535.9 5538.9 5203.49
Total Common Shares Outstanding 63.214 61.633 56.171 56.14 57.504
Cash 334.018 510.747 517.117 333.172 215.606
Capital Lease Obligations 5.21 6.269
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 3245.75 3009.85 2784.65 2606.14 2571.5
Cash and Short Term Investments 1585.69 1362.3 1167.91 881.482 899.358
Cash 366.1 331.37 424.139 334.018 296.686
Cash & Equivalents 409.59 650.934 563.772 517.464 542.672
Short Term Investments 810 380 180 30 60
Total Receivables, Net 729.236 683.194 681.154 651.493 601.179
Accounts Receivable - Trade, Net 627.841 610.389 623.938 651.493 601.179
Total Inventory 611.827 657.214 674.778 714.061 728.074
Prepaid Expenses 109.99 107.49 72.779 91.912 92.877
Other Current Assets, Total 209.009 199.653 188.028 267.192 250.016
Total Assets 11204.1 11260.5 11047.1 10835.3 10384.7
Property/Plant/Equipment, Total - Net 287.514 298.304 303.09 301.376 290.067
Property/Plant/Equipment, Total - Gross 412.333 418.749 419.23 409.023 388.038
Accumulated Depreciation, Total -124.819 -120.445 -116.14 -107.647 -97.971
Goodwill, Net 1705.32 1742.68 1723.44 1692.66 1592.64
Intangibles, Net 5417.86 5705.78 5764.21 5794.44 5570.39
Other Long Term Assets, Total 547.619 503.929 471.732 440.64 360.067
Total Current Liabilities 1573.33 945.265 908.902 933.193 812.954
Accounts Payable 109.85 98.428 125.454 90.758 102.249
Accrued Expenses 753.978 746.65 711.779 803.255 630.648
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 604.507 31 31 31 31
Other Current Liabilities, Total 104.994 69.187 40.669 8.18 49.057
Total Liabilities 7714.69 7734.87 7712.08 7749.52 7639.47
Total Long Term Debt 5110.76 5686.65 5689.66 5693.34 5695.81
Long Term Debt 5110.76 5686.65 5689.66 5693.34 5695.81
Deferred Income Tax 841.234 910.724 932.247 944.337 933.67
Other Liabilities, Total 189.372 192.23 181.273 178.65 197.035
Total Equity 3489.37 3525.68 3335.04 3085.73 2745.19
Common Stock 0.061 0.061 0.061 0.061 0.061
Additional Paid-In Capital 3639.94 3580.11 3511.73 3477.12 3388
Retained Earnings (Accumulated Deficit) 884.771 812.322 803.478 734.058 974.782
Other Equity, Total -1035.4 -866.823 -980.23 -1125.51 -1617.65
Total Liabilities & Shareholders’ Equity 11204.1 11260.5 11047.1 10835.3 10384.7
Total Common Shares Outstanding 62.945 63.398 63.987 63.214 62.89
Capital Lease Obligations
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -224.06 -329.668 238.616 523.367 447.098
Cash From Operating Activities 1271.98 778.507 899.648 776.401 798.904
Cash From Operating Activities 30.302 26.714 18.673 15.342 15.233
Amortization 599.169 525.769 259.58 354.814 201.498
Deferred Taxes -292.251 69.198 -136.937 -236.61 -88.815
Non-Cash Items 875.52 311.361 605.153 269.572 200.604
Cash Taxes Paid 94.681 271.217 226.823 183.61 164.217
Cash Interest Paid 270.671 138.271 42.47 43.002 42.706
Changes in Working Capital 283.297 175.133 -85.437 -150.084 23.286
Cash From Investing Activities -446.23 -5212.14 -1007.67 -155.3 -394.487
Capital Expenditures -498.194 -45.532 -379.254 -182.335 -131.47
Other Investing Cash Flow Items, Total 51.964 -5166.61 -628.416 27.035 -263.017
Cash From Financing Activities -529.491 3970.52 528.073 -293.745 -479.13
Financing Cash Flow Items -45.443 -35.602 -16.877 -16.739 -23.078
Issuance (Retirement) of Stock, Net 97.966 135.261 -46.856 -243.619 -430.335
Issuance (Retirement) of Debt, Net -582.014 3870.86 591.806 -33.387 -25.717
Foreign Exchange Effects -6.222 -3.207 0.374 0.366 -1.7
Net Change in Cash 290.034 -466.321 420.425 327.722 -76.413
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 69.42 -224.06 16.664 36.312 1.647
Cash From Operating Activities 320.708 1271.98 930.006 512.015 208.979
Cash From Operating Activities 7.574 30.302 22.958 15.364 7.617
Amortization 149.786 599.169 461.782 320.55 172.094
Deferred Taxes -66.061 -292.251 -146.874 -82.315 -45.339
Non-Cash Items 81.207 875.52 421.208 208.514 49.707
Changes in Working Capital 78.782 283.297 154.268 13.59 23.253
Cash From Investing Activities -4.822 -446.23 -121.852 -126.454 -37.292
Capital Expenditures -4.822 -498.194 -113.816 -118.718 -37.292
Other Investing Cash Flow Items, Total 51.964 -8.036 -7.736 0
Cash From Financing Activities -29.788 -529.491 -549.087 -260.034 -270.811
Financing Cash Flow Items -43.266 -45.443 -42.632 -40.065 -33.776
Issuance (Retirement) of Stock, Net 21.228 97.966 67.809 46.549 21.729
Issuance (Retirement) of Debt, Net -7.75 -582.014 -574.264 -266.518 -258.764
Foreign Exchange Effects 0.331 -6.222 -11.157 -5.71 -1.489
Net Change in Cash 286.429 290.034 247.91 119.817 -100.613
Cash Taxes Paid 94.681
Cash Interest Paid 270.671

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Jazz Pharma Company profile

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.

Equity composition

Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.

Industry: Pharmaceuticals (NEC)

Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

XRP/USD

0.50 Price
-0.120% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,366.01 Price
-0.700% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.40

BTC/USD

61,363.90 Price
-2.760% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,524.00 Price
-1.140% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading